Dfn-15
Wilson Disease
Alexion Pharmaceuticals, Inc.Phase 1Dormant
CC
46/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 89/ 100
Competitive context
12 Active assets in the Wilson Disease cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
ZINC ACETATE Nobelpharma | Phase 4 | BBB |
Teta 4Hcl Orphalan | Phase 3 | BBB |
ZINC D-GLUCONATE (1:2) Jun Li | Phase 4 | BBB |
Trientine Excelsior | Phase 3 | BB |
Penicillamine Orphalan | Phase 3 | BB |
View all 21 →
Same molecule, other indications
Dfn-15 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →